Neoplasms

All Conditions

Digestive System Diseases

Gland and Hormone Related Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Adenocarcinoma

Pancreatic Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Cystadenocarcinoma, Serous

Cystadenocarcinoma

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Cystic, Mucinous, and Serous

Pancreatic Cancer

Ovarian Cancer

Ovarian Epithelial Cancer

Biliary Tract Cancer

Adenocarcinoma of the Appendix

All Drugs and Chemicals

Antibodies

Immunoglobulins

During the Dose Escalation Stage, patients will be treated with ZB131 at increasing dose levels, beginning with a starting dose level (DL0) of 3 mg/kg once weekly, up to a maximum dose level (DL3) of 15 mg/kg once weekly.

ZB131 will be administered once weekly by intravenous infusion with the weight at baseline used for mg/kg dose calculations.

ZB131

Ramesh Ramanathan, MD

This study is a first-in-human, Phase 1, open label, multicenter, dose escalation study with expansion at the RP2D, to evaluate the safety, tolerability, and preliminary efficacy of ZB131 in patients with solid tumors where prevalence of CSP expression is high. Approximately 12 to 24 patients will be enrolled in the Dose Escalation Stage; the total number of patients will depend on the dose level at which the RP2D is defined. Patients who meet the eligibility criteria during Screening will enter the treatment period. ZB131 will be given via IV every week. Patients will be treated until disease progression or unacceptable toxicities occur.

This study is a first-in-human, Phase 1, open label, multicenter, dose escalation study with expansion at the RP2D, to evaluate the safety, tolerability, and preliminary efficacy of ZB131 in patients with solid tumors where prevalence of CSP expression is high. Approximately 12 to 24 patients will be enrolled in the Dose Escalation Stage; the total number of patients will depend on the dose level at which the RP2D is defined. Patients who meet the eligibility criteria during Screening will enter the treatment period. ZB131 will be given via IV every week. Patients will be treated until disease progression or unacceptable toxicities occur.

Once the RP2D has been established, the Dose Expansion stage will begin to enroll subjects by cohort. For each expansion cohort, subjects will be enrolled in two stages. The first stage includes an evaluation of 12 patients. If 1 or more of 12 patients have a CR or PR, then accrual will continue until a total of 37 patients with measurable disease have been enrolled. Additional patients may be added to ensure 37 subjects with measurable disease are available for evaluation

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A Cancer-Specific Plectin (CSP)-Targeting Functional Antibody in Solid Tumors That Are Likely to Express CSP

Determine maximum plasma concentration (Cmax)

ZielBio, Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors	NCT05074472	Solid Tumor, Ad... Pancreatic Duct... Ovarian Serous ... Biliary Cancer ... Ovarian Serous ...	ZB131	18 Years -	ZielBio, Inc.
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors	NCT05074472	Solid Tumor, Ad... Pancreatic Duct... Ovarian Serous ... Biliary Cancer ... Ovarian Serous ...	ZB131	18 Years -	ZielBio, Inc.
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors	NCT05074472	Solid Tumor, Ad... Pancreatic Duct... Ovarian Serous ... Biliary Cancer ... Ovarian Serous ...	ZB131	18 Years -	ZielBio, Inc.
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors	NCT05074472	Solid Tumor, Ad... Pancreatic Duct... Ovarian Serous ... Biliary Cancer ... Ovarian Serous ...	ZB131	18 Years -	ZielBio, Inc.

Spots Global Cancer Trial Database for pancreatic ductal; adenocarcinoma